TerminatedPhase 2NCT01013961
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Principal Investigator
- Clive S. Zent, MDUniversity of Rochester
- Intervention
- alemtuzumab(biological)
- Enrollment
- 31 target
- Eligibility
- 65 years · All sexes
- Timeline
- 2011 – 2015
Study locations (30)
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital, Fort Lauderdale, Florida, United States
- Ella Milbank Foshay Cancer Center at Jupiter Medical Center, Jupiter, Florida, United States
- CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
- Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler, Savannah, Georgia, United States
- Rush-Copley Cancer Care Center, Aurora, Illinois, United States
- Illinois CancerCare - Bloomington, Bloomington, Illinois, United States
- St. Joseph Medical Center, Bloomington, Illinois, United States
- Graham Hospital, Canton, Illinois, United States
- Illinois CancerCare - Canton, Canton, Illinois, United States
- Illinois CancerCare - Carthage, Carthage, Illinois, United States
- Memorial Hospital, Carthage, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Eureka Community Hospital, Eureka, Illinois, United States
- Illinois CancerCare - Eureka, Eureka, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01013961 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn